Pacific Edge strikes biotech deal with German firm

Dunedin biomedical company Pacific Edge Technology has licensed a German firm to commercialise a method for identifying patients at high risk of recurring colorectal cancer.

It signed an exclusive licence with Signature Diagnostics of Potsdam, which is to start a clinical validation trial on patients in Europe.